Latest Headlines

1. LOTTE Biologics Expands Antibody Manufacturing Agreement With Ottimo Pharma 5/18/2026

   LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.

2. AGC Biologics Joins Orphan Therapeutics Accelerator's Clinical Development Network As A Manufacturing Partner To Advance Cell And Gene Therapies For Ultra-Rare Diseases 5/14/2026

   Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling commercial access to stalled rare disease treatments, today announced that AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has joined OTXL’s Clinical Development Network (Orphan ClinDevNet) as a manufacturing partner.

3. Aldevron And Minaris Renew Lentiviral Plasmid Agreement 5/14/2026

   FARGO, N.D. & PHILADELPHIA–(BUSINESS WIRE)–Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider today announced a renewed licensing agreement that expands access to a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications.

4. Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery 5/12/2026

   Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

5. Made Scientific And RoosterBio Announce Strategic Technology And Supply Partnership To Expand Scalable MSC And Extracellular Vesicle Manufacturing 5/5/2026

   Partnership integrates RoosterBio's mesenchymal stem cell and extracellular vesicle platforms into Made Scientific's end-to-end CDMO capabilities to accelerate development and commercial-scale production of advanced therapies.

6. Ecolab Life Sciences Opens Bioprocessing Applications Lab In Korea To Support Downstream Process Development Across Asia 5/1/2026

   Ecolab Life Sciences is expanding the bioprocessing business with the launch of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, giving biopharmaceutical manufacturers across Asia better local access to downstream process development support. Strategically located to serve customers throughout the region, the site is Ecolab's first bioprocessing facility in Asia and joins an established applications network in the United States and the United Kingdom.

7. Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development 4/29/2026

   Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics.

8. AGC Biologics Wins 2026 Fierce Outsourcing Award For Leadership In Regulatory And Quality Compliance 4/27/2026

   AGC Biologics, your friendly CDMO expert, is the 2026 recipient of the Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance.

9. AES Cleanroom Technology appoints John Groth As Chief Revenue Officer 4/27/2026

   AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer as demand grows for flexible, high-performance manufacturing environments across pharma and biotech.

10. Minaris Delivers 100% Manufacturing And Release Success For Chimeric Therapeutics' CDH17 Autologous CAR‑T Program 4/23/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, “Chimeric” or the “Company”), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.